Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Paragon Care's Debt-to-EBITDA or its related term are showing as below:
ASX:PGC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.81 Med: 3.43 Max: 10.65
Current: 10.65
During the past 13 years, the highest Debt-to-EBITDA Ratio of Paragon Care was 10.65. The lowest was -1.81. And the median was 3.43.
ASX:PGC's Debt-to-EBITDA is ranked worse than 91.3% of 92
companies
in the Medical Distribution industry
Industry Median: 2.355
vs ASX:PGC: 10.65
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Paragon Care Debt-to-EBITDA Related Terms
Paragon Care Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Paragon Care's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PGC vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Paragon Care's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paragon Care Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Paragon Care's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Paragon Care's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Paragon Care (ASX:PGC) has a Debt-to-EBITDA of -476.01 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Paragon Care. According to the industry distribution chart, Paragon Care ranks #84 out of 92 companies in the Medical Distribution industry, placing it in the top 91.3%.
Is Paragon Care's Debt-to-EBITDA too high?
Paragon Care's current Debt-to-EBITDA is -476.01. Based on the distribution chart, Paragon Care ranks #84 out of 92 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Paragon Care has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Paragon Care's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Paragon Care ranks #84 out of 92 companies for Debt-to-EBITDA. This places Paragon Care in the lower half of its industry. The industry median Debt-to-EBITDA is 2.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.36, based on 92 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Paragon Care. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paragon Care's current Debt-to-EBITDA is -476.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paragon Care stock overvalued right now?
Based on GuruFocus' analysis, Paragon Care (ASX:PGC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.46, compared to a current price of A$0.14 — trading 70.7% below its estimated fair value. The current Debt-to-EBITDA is -476.01. Paragon Care's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Paragon Care (ASX:PGC), the current Debt-to-EBITDA is -476.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paragon Care (ASX:PGC) Overvalued in 2026?
Based on GuruFocus' analysis, Paragon Care stock appears to be undervalued.
The current stock price of A$0.14 is trading 70.7% below its estimated GF Value™ of A$0.46.
GuruFocus considers Paragon Care to be Possible Value Trap.
Key valuation signals for ASX:PGC:
Debt-to-EBITDA: -476.01
GF Value™: A$0.46 vs. price of A$0.14 (70.7% below fair value)
No single metric tells the full story. See the ASX:PGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paragon Care Ltd is a medical device company. The company provides medical equipment, devices, and consumables medical products to the healthcare market. The company provides solutions to various healthcare markets, aged care, and veterinary markets. The group is organized into two operating segments: ParagonCare and CH2 Holdings and the majority of its revenues are generated from the CH2 Holdings segment engaged in the distribution of pharmaceuticals, medical consumables, nutritional, and over-the-counter products to the healthcare market.
53GF Score
Get the complete analysis for ASX:PGC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PGC has been successfully added to your 
